# Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults

> **NCT07331545** · PHASE1 · NOT_YET_RECRUITING · sponsor: **Qilu Pharmaceutical Co., Ltd.** · enrollment: 70 (estimated)

## Conditions studied

- Metabolic Dysfunction-Associated Steatohepatitis(MASH)

## Interventions

- **DRUG:** QL2401
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT07331545
- **Lead sponsor:** Qilu Pharmaceutical Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** NOT_YET_RECRUITING
- **Start date:** 2026-01
- **Primary completion:** 2026-07
- **Final completion:** 2026-12
- **Target enrollment:** 70 (ESTIMATED)
- **Last updated:** 2026-01-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07331545

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07331545, "Safety, Tolerability, PK, PD, and Immunogenicity of QL2401 in Healthy Chinese Adults". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07331545. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*